Statin use is associated with faster achievement of CHR in pegylated IFN-α2–treated patients but shows no clear benefit in HU-treated patients. Kaplan-Meier plot showing time to CHR stratified by cytoreductive treatment and statin use. (A) Patients treated with IFN-α2 (n = 83). The median time to CHR was 19 months for non–statin users and 7 months for statin users. (B) Patients treated with HU (n = 46). The median time to CHR was 15 months for non–statin users and 9 months for statin users. The log-rank test was used to compare the cumulative incidence of CHR. w/o, without.